Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Better After CHoosing
NL-OMON23900Not yet recruiting
- Sponsor
- investigator initiated trial by Rheumatology Research Center Northern Netherlands
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of filgotinib, etanercept and adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by investigator initiated trial by Rheumatology Research Center Northern Netherlands. Primary endpoints: Proportion choosing filgotinib at baseline and Treatment satisfaction at week 24. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON23900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23900.